查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1801391

脊髓灰質炎疫苗市場報告：2031 年趨勢、預測與競爭分析

Poliomyelitis Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球脊髓灰質炎疫苗市場前景光明，疫苗接種相關疫苗 (VAPP) 和疫苗衍生小兒麻痺疫苗 (VDPV) 市場蘊藏著機會。預計2025年至2031年期間，全球脊髓灰質炎疫苗市場的複合年成長率將達到2.3%。市場的主要驅動力包括：疫苗接種意識的提升、常規疫苗接種需求的增加，以及政府和機構的大力資金投入和支持。

  • Lucintel 預測，隨著對易於管理、無針免疫接種方式的需求不斷增加，口服脊髓灰質炎疫苗的使用將推動脊髓灰質炎在預測期內實現高速成長。
  • 從應用來看，由於人們對 VDPV 疫情的擔憂日益加劇，預計 VDPV 將出現高速成長，這推動了對有針對性的疫苗接種策略的需求。
  • 按地區分類，預計北美在預測期內將經歷最高的成長。

脊髓灰質炎疫苗市場的新趨勢

全球脊髓灰質炎疫苗市場瞬息萬變，疫苗配方、分發和免疫接種計畫面臨新的挑戰和機會。近期趨勢主要集中在持續努力根除脊髓灰質炎、擴大疫苗在被忽視地區的覆蓋範圍以及應對疫苗衍生脊髓灰質炎病毒疫情。以下是影響全球脊髓灰質炎疫苗市場的五大新興趨勢。

  • 去活化脊髓灰質炎疫苗自動化程度不斷提升：隨著疫苗衍生脊髓灰質炎(VDPV) 指示病例在世界各地拉響警報，大多數國家正在從口服脊髓灰質炎疫苗 (OPV) 過渡到去活化小兒麻痺疫苗 (IPV)。 IPV 能夠在維持免疫力的同時消除 VDPV 的風險，使其成為確保根除脊髓灰質炎的關鍵組成部分。這項過渡在免疫覆蓋率低和醫療基礎設施薄弱的地區尤為關鍵。 IPV 的全球市場正在不斷擴大，因為它能夠安全、長期地維持對脊髓灰質炎的免疫力，同時最大限度地降低脊髓灰質炎復發的可能性。
  • 加強監測和監控：隨著全球根除脊髓灰質炎的目標日益臨近，加強監測系統以發現和監控脊髓灰質炎傳播的需求日益增加。監測不僅包括病毒基因組成，還包括改善事件報告和追蹤疫苗接種覆蓋率。對於那些多年來已無脊髓灰質炎、但由於疫苗接種率低或移民人數眾多而面臨風險的國家，監測也至關重要。加強監測對於及早發現疫情並早期療育以阻止感染蔓延至關重要。
  • 將疫苗接種工作與其他國家策略相協調：一些國家正在採用這項策略來提高脊髓灰質炎疫苗接種覆蓋率，同時降低營運成本。此類綜合方法旨在透過將脊髓灰質炎疫苗接種與麻疹和乙肝疫苗接種相結合，或透過提高常規疫苗對有需要兒童的可及性來提高覆蓋率。這在低收入和偏遠地區（醫療機構較遠）變得越來越重要。將兒童納入現有計畫也有助於改善整體免疫接種和公共衛生體系。
  • 新型脊髓灰質炎疫苗的研發：新型聯合疫苗和改良劑型正在研發中。這些疫苗可能能夠增強免疫反應，促進疫苗遞送，並提高運輸和儲存所需的穩定性。此外，針對兒童疫苗（包括脊髓灰質炎與其他疫苗的合併使用）的新型佐劑和遞送系統也正在研發中。這些創新可能提供更好的選擇，尤其是在後勤受限或疫情模式正在顯現的地區。
  • 私部門和官民合作關係：私人企業正擴大參與全球脊髓灰質炎免疫宣傳活動，製藥公司也投資於疫苗的生產、行銷和研發。官民合作關係關係是對脊髓灰質炎根除策略的有效補充，尤其是在資源匱乏的地區。這些合作支持中低收入國家建立疫苗儲備並進行定價，從而加強全球脊髓灰質炎根除工作。

隨著世界朝著根除脊髓灰質炎的目標快速邁進，全球脊髓灰質炎疫苗市場出現了一些新興趨勢，例如使用小兒麻痺疫苗（IPV）、加強監測以及將疫苗納入免疫計劃，這些趨勢在市場上得到了強烈的體現。這些趨勢正在增加疫苗的可得性，增強脊髓灰質炎疫苗的安全性，並提高全球管理效率。此外，新型疫苗的出現和發展，以及官民合作關係關係，正在幫助克服大規模免疫宣傳活動中的後勤和資金限制。

脊髓灰質炎疫苗市場的最新趨勢

全球脊髓灰質炎疫苗市場的最新變化是經過深思熟慮的，重點關注對全球根除脊髓灰質炎宣傳活動成功至關重要的因素，包括引入小兒麻痺加強劑、生產創新、分銷創新以及國際合作。脊髓灰質炎免疫策略的發展進展將提高免疫覆蓋率，並將非代表性族群納入其中，有助於實現全球根除脊髓灰質炎和消除疫苗衍生株的最終目標。以下是塑造全球脊髓灰質炎疫苗市場未來的五個關鍵發展。

  • 全球從口服脊髓灰質炎疫苗 (OPV) 向去活化小兒麻痺疫苗 (IPV) 過渡：全球從口服小兒麻痺疫苗 (OPV) 向去活化脊髓灰質炎疫苗 (IPV) 過渡是脊髓灰質炎疫苗市場的重大變革之一。 IPV 消除了疫苗相關脊髓灰質炎(VAP) 的風險，而這正是 OPV 面臨的挑戰。世界衛生組織 (WHO) 和其他衛生組織倡導這一轉變，以安全地增強免疫力。 IPV 已被納入國家免疫接種計劃，以確保全球根除小兒麻痺宣傳活動順利推進。
  • 在常規免疫接種計劃中，IPV 的使用有所改善：印度和中國等國家已將 IPV 納入其常規免疫計劃，以幫助其對抗脊髓灰質炎。在根除小兒麻痺的最後階段，將 IPV 與 OPV 合併使用，有助於維持人群免疫力，同時又不會增加 VDPV 疫情的威脅。這兩種方法相輔相成，加強了免疫宣傳活動，並有助於預防脊髓灰質炎復發。
  • 加強監測：透過更嚴格的監測系統，脊髓灰質炎傳播正得到有效控制。脊髓灰質炎基因定序、改進的報告系統和即時資訊對於及早發現疫情至關重要。這些進展使得快速反應成為可能，尤其是在受影響國家，並使疫苗接種能夠盡快進行。這有助於確保不遺漏任何新的脊髓灰質炎病例，並為根除脊髓灰質炎的最後衝刺提供強力的支持。
  • 加大全球對根除脊髓灰質炎工作的投入：世界衛生組織、各國政府和私人機構為全球根除脊髓灰質炎行動（GPEI）等計劃提供了大量資金支持。這些投入促進了疫苗宣傳活動和接種工作，即使在疫苗匱乏和受衝突影響的地區也是如此。衛生基礎設施的加強和資金支持為免疫接種計畫的成功做出了重要貢獻，使脊髓灰質炎始終成為全球衛生的焦點。
  • 官民合作關係促進疫苗可及性：葛蘭素史克和賽諾菲等公司正與國際衛生組織合作，在眾多低收入和服務欠缺地區擴大脊髓灰質炎疫苗的可及性，發揮著至關重要的作用。這項工作旨在克服高成本、物流挑戰和醫療服務不足等障礙，使更多國家能夠獲得疫苗。此類合作有助於發展疫苗庫存，改善疫苗分發，並擴大全球疫苗生產規模。

全球脊髓灰質炎疫苗市場的最新發展凸顯了過渡、監測、資金籌措和合作在對抗脊髓灰質炎中的重要性。支持接種小兒麻痺疫苗（IPV）、改善監測以及公私合營正在加強全球疫苗接種工作。這些努力，加上應對疫苗相關挑戰和疫情，正在使世界更接近根除脊髓灰質炎的目標。目前，市場正致力於在世界各地實施持續的疫苗接種和監測項目，以確保根除脊髓灰質炎的目標仍然可行。

目錄

第1章執行摘要

第2章 市場概述

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業驅動力與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球脊髓灰質炎疫苗市場（按類型）

  • 概述
  • 吸引力分析：按類型
  • 脊髓灰質炎疫苗 I：趨勢與預測（2019-2031）
  • 脊髓灰質炎疫苗 II：趨勢與預測（2019-2031）
  • 脊髓灰質炎疫苗 III：趨勢與預測（2019-2031）
  • 口服脊髓灰質炎疫苗：趨勢與預測（2019-2031）

第5章 全球脊髓灰質炎疫苗市場（依應用）

  • 概述
  • 吸引力分析：按用途
  • VAPP：趨勢與預測（2019-2031）
  • VDPV：趨勢與預測（2019-2031）

第6章區域分析

  • 概述
  • 全球脊髓灰質炎疫苗市場（按地區）

第7章北美脊髓灰質炎疫苗市場

  • 概述
  • 北美脊髓灰質炎疫苗市場（按類型）
  • 北美脊髓灰質炎疫苗市場（依應用）
  • 美國脊髓灰質炎疫苗市場
  • 墨西哥的脊髓灰質炎疫苗市場
  • 加拿大脊髓灰質炎疫苗市場

第8章 歐洲脊髓灰質炎疫苗市場

  • 概述
  • 歐洲脊髓灰質炎疫苗市場（按類型）
  • 歐洲脊髓灰質炎疫苗市場（依應用）
  • 德國脊髓灰質炎疫苗市場
  • 法國脊髓灰質炎疫苗市場
  • 西班牙的脊髓灰質炎疫苗市場
  • 義大利脊髓灰質炎疫苗市場
  • 英國脊髓灰質炎疫苗市場

第9章 亞太地區脊髓灰質炎疫苗市場

  • 概述
  • 亞太地區脊髓灰質炎疫苗市場（按類型）
  • 亞太地區脊髓灰質炎疫苗市場（依應用）
  • 日本脊髓灰質炎疫苗市場
  • 印度脊髓灰質炎疫苗市場
  • 中國脊髓灰質炎疫苗市場
  • 韓國脊髓灰質炎疫苗市場
  • 印尼脊髓灰質炎疫苗市場

第10章 其他地區（ROW）脊髓灰質炎市場

  • 概述
  • 世界其他地區（ROW）脊髓灰質炎疫苗市場（按類型）
  • 世界其他地區（ROW）脊髓灰質炎疫苗市場（按應用）
  • 中東脊髓灰質炎疫苗市場
  • 南美洲脊髓灰質炎疫苗市場
  • 非洲脊髓灰質炎疫苗市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市場佔有率分析

第12章機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按類型分類的成長機會
    • 成長機會：按應用
  • 全球脊髓灰質炎疫苗市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 企業合併（M&A）、協議、合作與合資企業

第13章 價值鏈主要企業概況

  • Competitive Analysis
  • GSK
  • Sanofi-Pasteur
  • Merck
  • Crucell
  • China National Biotech Group

第14章 附錄

  • 圖片列表
  • 表格列表
  • 分析方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於 Lucintel
  • 詢問

The future of the global poliomyelitis vaccine market looks promising with opportunities in the VAPP, VDPV markets. The global poliomyelitis vaccine market is expected to grow with a CAGR of 2.3% from 2025 to 2031. The major drivers for this market are the growing awareness about immunization and the need for routine vaccinations, and the strong funding and support from governments and organizations.

  • Lucintel forecasts that, within the type category, the oral poliomyelitis vaccine is expected to witness higher growth over the forecast period due to the growing demand for easy-to-administer and needle-free vaccination options, which is boosting oral polio vaccine use.
  • Within the application category, VDPV is expected to witness higher growth due to rising concerns over VDPV outbreaks, which are driving demand for targeted vaccination strategies.
  • In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Poliomyelitis Vaccine Market

The global poliomyelitis vaccine market is constantly changing as there are new challenges and new opportunities when it comes to vaccine formulation, distribution, and immunization plans. The recent trends are targeting the perpetual efforts to eradicate polio, widening the scope of available vaccines in neglected areas, and addressing the problems of outbreaks of vaccine-derived poliovirus. Below are five emerging trends that are persistent in the shaping of the global poliomyelitis vaccine market.

  • Increasing automation of the inactivated polio vaccine: As the vaccine-derived poliovirus (VDPV) index cases have raised alarm bells around the world, most countries are transitioning from oral polio vaccine (OPV) to IPV. IPV also removes the VDPV risk but preserves immunity, which remains critical in ensuring that polio eradication is achieved. This transition is most relevant in regions with poor immunization rates and weak healthcare infrastructure. The world market for IPV is expanding owing to its ability to provide safe and long-term immunity against polio with minimal chances of another outbreak.
  • Growing emphasis on surveillance and monitoring: With the goal of eradicating polio from the entire globe, there is an increasing need to strengthen the surveillance system to detect and monitor poliovirus transmission. Surveillance includes not only the genetic makeup of the virus but also improvements in the reporting of events and tracking vaccination coverage. Surveillance is vital even for countries that have already been polio-free for years but pose risks due to low vaccination coverage or migration patterns. These enhancements are critical for the early detection of outbreaks and limiting potential spread through early interventions.
  • Vaccination deliveries linked with other national strategies: Some countries are using this strategy to improve the coverage of polio vaccination while at the same time reducing operational expenditures. Such integrated approaches target increased coverage by interspersing polio vaccinations with measles or hepatitis B and improving the availability of various routine vaccines to children, which would otherwise go unvaccinated. This is becoming a more crucial trend in low-income and hard-to-reach areas where distances to healthcare facilities are vast. Integrating children into available programs also improves the general immunization system and the public health systems.
  • Development of new types of polio vaccines: Novel combination vaccines and improved formulations are under development. These vaccines are expected to improve the immune response, ease vaccine delivery, and improve stability features required for transport and storage. New adjuvants or delivery systems, as well as combined vaccines, e.g., polio with other vaccines administered to children, are being investigated. Such innovations may offer better options, especially in areas that have logistical constraints or where there are new patterns of outbreaks.
  • Private sector and public-private partnerships: Participation of the private sector in the global polio vaccination campaign has risen, with pharmaceutical companies investing towards vaccine manufacturing, marketing, and research. Public-private partnerships are effective in complementing polio eradication strategies, particularly in resource-constrained settings. Such collaborations assist in developing vaccine stocks and pricing for lower- and middle-income countries, thus enhancing global polio eradication efforts.

As the world moves rapidly towards the goal of eradicating polio, trends such as the usage of IPV, improved issues on surveillance, or the streamlining of vaccines with immunization programs are strong emerging trends in the global poliomyelitis vaccine market. These trends are enhancing the availability of vaccines, increasing the safety of polio vaccines, and improving the efficiency of administration worldwide. And, as in the case of public-private partnerships, new types of vaccines and their development are helping to overcome logistical and financial constraints on wide-scale immunization campaigns.

Recent Developments in the Poliomyelitis Vaccine Market

The latest changes in the global poliomyelitis vaccine market are purposeful, as they draw attention to factors such as the introduction of an IPV booster dose, production innovations, distribution innovations, and international cooperation, which are crucial for the global success of the polio eradication campaign. Progress in the development of polio vaccination strategies contributes to the targeted end goal, which is the global eradication of polio and elimination of vaccine-derived strains, increasing vaccination coverage, and including non-represented people. Below are five key developments shaping the future of the global poliomyelitis vaccine market.

  • Global move from OPV usage towards IPV: The global movement from the use of oral polio vaccine (OPV) to inactivated polio vaccine (IPV) is one of the major changes in the poliomyelitis vaccine market. With IPV, countries do not have the risk of vaccine-associated poliovirus (VAP), which was a challenge with OPV in some settings. This change is advocated by WHO and other health organizations to enhance immunity safely. IPV doses are incorporated into national immunization schedules to keep the objectives of the global eradication campaign on track.
  • IPV use improved in routine immunization schedules: Countries like India, China, and others have already incorporated IPV into their routine vaccination programs, aiding in the fight against polio. The use of IPV with OPV during the last stages of eradication has helped maintain population immunity without heightening the threat of VDPV outbreaks. The two approaches supplement each other and help enhance vaccination campaigns, preventing re-emergence of polio.
  • Enhanced systems of surveillance: The transmission of polio has been effectively controlled through stricter surveillance systems. Polio virus strain genetic sequencing, improved reporting systems, and real-time information have become indispensable for early detection of outbreaks. Such advancements allow for rapid response measures, especially in countries where outbreaks have occurred, ensuring that immunization takes place as quickly as possible. This guarantees that no new cases of polio are missed and strengthens the final push to end the disease.
  • Greater contributions worldwide for polio eradication efforts: Significant funding from global health organizations, governments, and private entities has been received, notably supporting projects like the Global Polio Eradication Initiative (GPEI). These investments facilitate vaccine marketing campaigns and administration, even in rare and conflict-hit areas. Reinforcing health infrastructure and financial backing has significantly contributed to the success of vaccination programs and kept polio as a focus in global health.
  • Public-private partnerships for accessible vaccines: Companies like GSK, Sanofi, and others working with international health organizations have played a key role by making polio vaccines available and affordable in many low-income and underserved areas. Efforts aim to make vaccine access possible in more countries by overcoming barriers such as high costs, logistical issues, and inadequate healthcare provision. Such collaborations help develop vaccine stocks, improve distribution, and expand global vaccine manufacturing activities.

Recent developments in the global poliomyelitis vaccine market highlight the importance of transitions, surveillance, funding, and collaborations in the fight against polio. Support for IPV introduction, improved surveillance, and public-private partnerships have enhanced the global push for vaccination. These efforts, combined with addressing vaccine-related challenges and outbreaks, are bringing the world closer to the elimination of polio. The market now focuses on ensuring that polio remains eradicated through sustained immunization and surveillance programs worldwide.

Strategic Growth Opportunities in the Poliomyelitis Vaccine Market

The world's poliomyelitis vaccine market is experiencing acceleration in development owing to challenges posed to polio eradication: mass vaccinations, improvements in vaccine development and dissemination, global cooperation, etc. Now that polio has been eradicated in most places, the challenge is to eliminate this disease entirely and focus on new challenges. The market is still developing and offers possibilities for new strategies in producing, distributing, and monitoring vaccines. In particular, with most countries switching from the oral form of the polio vaccine to the inactivated type, here are five growth opportunities that will cut across sectors in the poliomyelitis vaccine market.

  • Increasing usage of IPV within routine immunization schedules: The transition from OPV to IPV brings potential for increased revenue. IPV offers enhanced safety as residual VDPV is absent. Continued use of IPV in countries that have achieved polio-free status will help protect against resurgence. This change necessitates increased capacity in vaccine manufacturing, cold chain logistics, and regulatory frameworks, providing growth avenues for manufacturers and health organizations.
  • The use of combination vaccines to eradicate polio circulation: Including polio vaccines in DTP (diphtheria, tetanus, pertussis) vaccines enhances the market. Combining polio vaccination with wider immunization activities lowers operational costs and raises coverage. This strategy stimulates demand for combination vaccines, which is cost-effective for manufacturers and health agencies aiming to immunize every child.
  • Opportunities and constraints regarding polio surveillance and monitoring technologies: Advanced surveillance technology is critical for global eradication, offering opportunities in genomic surveillance, diagnostic technologies, handheld health devices, and real-time reporting systems. Reinforcing surveillance networks is especially important in weak health system areas or where polio is still endemic. This creates opportunities for diagnostic testing services and data analysis.
  • Polio vaccine manufacturing and supply chain improvements: The increasing demand for vaccines creates growth opportunities for manufacturing and distribution. Improving vaccine formulation and supply chain management is critical for consistent supply, especially in remote or conflict-affected regions. Collaboration between public health agencies and private companies will enhance market profitability and effectiveness.
  • Public-private partnerships for polio eradication: PPPs have become effective in increasing vaccination coverage in underserved regions. These partnerships enable increased funding, resource sharing, and expertise, helping to overcome geographical and financial barriers. Securing investments through these partnerships enhances rapid deployment, infrastructure development, and manufacturing expansion.

The scenario of the poliomyelitis vaccine market globally looks favorable, with several growth opportunities such as vaccine proliferation, collaboration with other vaccine programs, technology integration for surveillance, improved manufacturing processes, and public-private partnerships. These opportunities support efforts to achieve polio eradication and sustained immunity in the post-eradication period. Synergistic actions between manufacturers, international health bodies, and governments are essential for enhancing vaccination, supply chain management, and surveillance.

Poliomyelitis Vaccine Market Driver and Challenges

There are many factors affecting the global market of poliomyelitis vaccines, including technological innovations, economic factors, and regulations. These factors influence vaccine purchase, vaccination processes, and the effectiveness of global eradication efforts. However, there are setbacks such as vaccine-derived poliovirus outbreaks, logistical issues, and regional heterogeneity in immunization, which remain challenges. It is important to assess and understand the factors driving and restraining the poliomyelitis vaccine market to succeed.

The factors responsible for driving the Poliomyelitis Vaccine market include:

1. Global campaigns for polio eradication: Led by the Global Polio Eradication Initiative (GPEI), involving WHO, UNICEF, and the Rotary Foundation, supported by substantial funding and political will, improving vaccination levels and supply, and establishing demand for OPV and IPV.

2. Shift toward IPV: The transition from OPV to IPV in immunization programs, especially in polio-free countries, to address VDPV concerns, increasing demand for IPV vaccines.

3. Technological advancements in vaccine production: Innovations such as recombinant DNA, adjuvants, and new formulations reduce costs and increase vaccine availability, especially in poor and conflict-affected regions.

4. Enhanced vaccine availability in developing economies: Initiatives like GAVI make vaccines accessible at reasonable prices, helping restore coverage in endemic areas.

5. Global networking and financial support: International funding and sponsorship support ongoing vaccination, research, and health system strengthening.

Challenges include:

1. Vaccine-derived poliovirus (VDPV): Outbreaks of VDPV, especially with OPV, pose a major obstacle. WHO advocates for IPV to eliminate this risk, but high costs and logistical issues hinder widespread adoption.

2. Logistical challenges: Distribution issues in rural and conflict zones, cold chain problems, wastage, and transportation hurdles.

3. Political conditions and conflict zones: Ongoing violence and conflict, especially in Afghanistan and Pakistan, hinder vaccination efforts.

International cooperation, improved mechanisms, and persistent efforts are necessary to eradicate poliomyelitis globally. Addressing challenges like VDPV, logistics, and socio-political issues is crucial for effective immunization programs.

List of Poliomyelitis Vaccine Companies

Companies in the market compete based on product quality. Major players focus on expanding manufacturing, R&D, infrastructure, and leveraging integration across the value chain. These strategies help cater to increasing demand, develop innovative products, reduce costs, and expand customer bases. Some of the companies profiled include:

  • GSK
  • Sanofi-Pasteur
  • Merck
  • Crucell
  • China National Biotech Group

Poliomyelitis Vaccine Market by Segment

The study includes a forecast for the global poliomyelitis vaccine market by type, application, and region.

Poliomyelitis Vaccine Market by Type [Value from 2019 to 2031]:

  • Poliomyelitis Vaccine I
  • Poliomyelitis Vaccine II
  • Poliomyelitis Vaccine III
  • Oral Poliomyelitis Vaccine

Poliomyelitis Vaccine Market by Application [Value from 2019 to 2031]:

  • VAPP
  • VDPV

Poliomyelitis Vaccine Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Poliomyelitis Vaccine Market

The global poliomyelitis vaccine market has been a concern for numerous decades. The highly contagious disease, if left unmanaged, can lead to death or paralysis. Efforts to eliminate the disease have been mostly successful owing to advancements in polio vaccines. In countries such as the USA, China, Germany, India, and Japan, recent advancements focus on expanding vaccine distribution, managing outbreaks, and providing assistance with the last phase of elimination. Improvements in diffusion methods and timing, localized educational programs, and closer collaboration between global health agencies are expected to advance vaccination efforts in these areas.

  • United States: Despite being at the forefront of polio vaccination and eradication efforts, occasional outbreaks from vaccine strains occur due to OPV. Prevention strategies include promoting IPV use. The CDC has expanded surveillance systems, ensured robust vaccination programs, and supports global eradication efforts. Maintaining polio-free certification through continuous investments and immunity is paramount.
  • China: China has made significant progress in combating poliomyelitis, switching from OPV to IPV in 2016. Efforts include enhancing immunization systems, routine vaccination coverage, and vaccine supply chain management. China collaborates with WHO and other organizations, though challenges remain in large rural populations and migration.
  • Germany: Germany remains a key player in global polio eradication, vaccinating with IPV only, maintaining high coverage, and participating in campaigns like GPEI. The country emphasizes awareness among migrants to ensure access to vaccination. Its strong healthcare system supports these efforts.
  • India: India was declared polio-free in 2014 after decades of vaccination campaigns. Current efforts focus on maintaining this status and increasing immunization coverage, especially among marginalized and rural communities, with active government involvement.
  • Japan: Japan has maintained excellent polio vaccination coverage for decades, employing IPV-only strategies. It supports international campaigns and has strengthened its health system to prevent reintroduction, serving as a leader in global health.

Features of the Global Poliomyelitis Vaccine Market

  • Market Size Estimates: Estimation of market size in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by segments and regions.
  • Segmentation Analysis: Market size by type, application, and region in dollar value.
  • Regional Analysis: Breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities across types, applications, and regions.
  • Strategic Analysis: Includes M&A, new product development, and competitive landscape.

Industry competitiveness based on Porter's Five Forces model.

This report answers the following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the poliomyelitis vaccine market by type (poliomyelitis vaccine I, II, III, and oral poliomyelitis vaccine), application (VAPP and VDPV), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Poliomyelitis Vaccine Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Poliomyelitis Vaccine I: Trends and Forecast (2019-2031)
  • 4.4 Poliomyelitis Vaccine II: Trends and Forecast (2019-2031)
  • 4.5 Poliomyelitis Vaccine III: Trends and Forecast (2019-2031)
  • 4.6 Oral Poliomyelitis Vaccine: Trends and Forecast (2019-2031)

5. Global Poliomyelitis Vaccine Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 VAPP: Trends and Forecast (2019-2031)
  • 5.4 VDPV: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Poliomyelitis Vaccine Market by Region

7. North American Poliomyelitis Vaccine Market

  • 7.1 Overview
  • 7.2 North American Poliomyelitis Vaccine Market by Type
  • 7.3 North American Poliomyelitis Vaccine Market by Application
  • 7.4 United States Poliomyelitis Vaccine Market
  • 7.5 Mexican Poliomyelitis Vaccine Market
  • 7.6 Canadian Poliomyelitis Vaccine Market

8. European Poliomyelitis Vaccine Market

  • 8.1 Overview
  • 8.2 European Poliomyelitis Vaccine Market by Type
  • 8.3 European Poliomyelitis Vaccine Market by Application
  • 8.4 German Poliomyelitis Vaccine Market
  • 8.5 French Poliomyelitis Vaccine Market
  • 8.6 Spanish Poliomyelitis Vaccine Market
  • 8.7 Italian Poliomyelitis Vaccine Market
  • 8.8 United Kingdom Poliomyelitis Vaccine Market

9. APAC Poliomyelitis Vaccine Market

  • 9.1 Overview
  • 9.2 APAC Poliomyelitis Vaccine Market by Type
  • 9.3 APAC Poliomyelitis Vaccine Market by Application
  • 9.4 Japanese Poliomyelitis Vaccine Market
  • 9.5 Indian Poliomyelitis Vaccine Market
  • 9.6 Chinese Poliomyelitis Vaccine Market
  • 9.7 South Korean Poliomyelitis Vaccine Market
  • 9.8 Indonesian Poliomyelitis Vaccine Market

10. ROW Poliomyelitis Vaccine Market

  • 10.1 Overview
  • 10.2 ROW Poliomyelitis Vaccine Market by Type
  • 10.3 ROW Poliomyelitis Vaccine Market by Application
  • 10.4 Middle Eastern Poliomyelitis Vaccine Market
  • 10.5 South American Poliomyelitis Vaccine Market
  • 10.6 African Poliomyelitis Vaccine Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Poliomyelitis Vaccine Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 GSK
    • Company Overview
    • Poliomyelitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Sanofi-Pasteur
    • Company Overview
    • Poliomyelitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Merck
    • Company Overview
    • Poliomyelitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Crucell
    • Company Overview
    • Poliomyelitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 China National Biotech Group
    • Company Overview
    • Poliomyelitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Poliomyelitis Vaccine Market
  • Figure 2.1: Usage of Poliomyelitis Vaccine Market
  • Figure 2.2: Classification of the Global Poliomyelitis Vaccine Market
  • Figure 2.3: Supply Chain of the Global Poliomyelitis Vaccine Market
  • Figure 2.4: Driver and Challenges of the Poliomyelitis Vaccine Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Poliomyelitis Vaccine Market ($B) by Type
  • Figure 4.3: Forecast for the Global Poliomyelitis Vaccine Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Poliomyelitis Vaccine I in the Global Poliomyelitis Vaccine Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Poliomyelitis Vaccine II in the Global Poliomyelitis Vaccine Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Poliomyelitis Vaccine III in the Global Poliomyelitis Vaccine Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Oral Poliomyelitis Vaccine in the Global Poliomyelitis Vaccine Market (2019-2031)
  • Figure 5.1: Global Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Poliomyelitis Vaccine Market ($B) by Application
  • Figure 5.3: Forecast for the Global Poliomyelitis Vaccine Market ($B) by Application
  • Figure 5.4: Trends and Forecast for VAPP in the Global Poliomyelitis Vaccine Market (2019-2031)
  • Figure 5.5: Trends and Forecast for VDPV in the Global Poliomyelitis Vaccine Market (2019-2031)
  • Figure 6.1: Trends of the Global Poliomyelitis Vaccine Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Poliomyelitis Vaccine Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Poliomyelitis Vaccine Market (2019-2031)
  • Figure 7.2: North American Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Poliomyelitis Vaccine Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Poliomyelitis Vaccine Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Poliomyelitis Vaccine Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Poliomyelitis Vaccine Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Poliomyelitis Vaccine Market (2019-2031)
  • Figure 8.2: European Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Poliomyelitis Vaccine Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Poliomyelitis Vaccine Market ($B) by Type (2025-2031)
  • Figure 8.5: European Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Poliomyelitis Vaccine Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Poliomyelitis Vaccine Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Poliomyelitis Vaccine Market (2019-2031)
  • Figure 9.2: APAC Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Poliomyelitis Vaccine Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Poliomyelitis Vaccine Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Poliomyelitis Vaccine Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Poliomyelitis Vaccine Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Poliomyelitis Vaccine Market (2019-2031)
  • Figure 10.2: ROW Poliomyelitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Poliomyelitis Vaccine Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Poliomyelitis Vaccine Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Poliomyelitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Poliomyelitis Vaccine Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Poliomyelitis Vaccine Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Poliomyelitis Vaccine Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Poliomyelitis Vaccine Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Poliomyelitis Vaccine Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Poliomyelitis Vaccine Market by Type
  • Figure 12.2: Growth Opportunities for the Global Poliomyelitis Vaccine Market by Application
  • Figure 12.3: Growth Opportunities for the Global Poliomyelitis Vaccine Market by Region
  • Figure 12.4: Emerging Trends in the Global Poliomyelitis Vaccine Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Poliomyelitis Vaccine Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Poliomyelitis Vaccine Market by Region
  • Table 1.3: Global Poliomyelitis Vaccine Market Parameters and Attributes
  • Table 3.1: Trends of the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 3.2: Forecast for the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Poliomyelitis Vaccine Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 4.4: Trends of Poliomyelitis Vaccine I in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 4.5: Forecast for Poliomyelitis Vaccine I in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 4.6: Trends of Poliomyelitis Vaccine II in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 4.7: Forecast for Poliomyelitis Vaccine II in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 4.8: Trends of Poliomyelitis Vaccine III in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 4.9: Forecast for Poliomyelitis Vaccine III in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 4.10: Trends of Oral Poliomyelitis Vaccine in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 4.11: Forecast for Oral Poliomyelitis Vaccine in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Poliomyelitis Vaccine Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 5.4: Trends of VAPP in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 5.5: Forecast for VAPP in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 5.6: Trends of VDPV in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 5.7: Forecast for VDPV in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Poliomyelitis Vaccine Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Poliomyelitis Vaccine Market (2025-2031)
  • Table 7.1: Trends of the North American Poliomyelitis Vaccine Market (2019-2024)
  • Table 7.2: Forecast for the North American Poliomyelitis Vaccine Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Poliomyelitis Vaccine Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Poliomyelitis Vaccine Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Poliomyelitis Vaccine Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Poliomyelitis Vaccine Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Poliomyelitis Vaccine Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Poliomyelitis Vaccine Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Poliomyelitis Vaccine Market (2019-2031)
  • Table 8.1: Trends of the European Poliomyelitis Vaccine Market (2019-2024)
  • Table 8.2: Forecast for the European Poliomyelitis Vaccine Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Poliomyelitis Vaccine Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Poliomyelitis Vaccine Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Poliomyelitis Vaccine Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Poliomyelitis Vaccine Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Poliomyelitis Vaccine Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Poliomyelitis Vaccine Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Poliomyelitis Vaccine Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Poliomyelitis Vaccine Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Poliomyelitis Vaccine Market (2019-2031)
  • Table 9.1: Trends of the APAC Poliomyelitis Vaccine Market (2019-2024)
  • Table 9.2: Forecast for the APAC Poliomyelitis Vaccine Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Poliomyelitis Vaccine Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Poliomyelitis Vaccine Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Poliomyelitis Vaccine Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Poliomyelitis Vaccine Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Poliomyelitis Vaccine Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Poliomyelitis Vaccine Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Poliomyelitis Vaccine Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Poliomyelitis Vaccine Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Poliomyelitis Vaccine Market (2019-2031)
  • Table 10.1: Trends of the ROW Poliomyelitis Vaccine Market (2019-2024)
  • Table 10.2: Forecast for the ROW Poliomyelitis Vaccine Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Poliomyelitis Vaccine Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Poliomyelitis Vaccine Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Poliomyelitis Vaccine Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Poliomyelitis Vaccine Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Poliomyelitis Vaccine Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Poliomyelitis Vaccine Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Poliomyelitis Vaccine Market (2019-2031)
  • Table 11.1: Product Mapping of Poliomyelitis Vaccine Suppliers Based on Segments
  • Table 11.2: Operational Integration of Poliomyelitis Vaccine Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Poliomyelitis Vaccine Revenue
  • Table 12.1: New Product Launches by Major Poliomyelitis Vaccine Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Poliomyelitis Vaccine Market